Navigation Links
Arno Therapeutics Announces New Ticker Symbol
Date:7/17/2008

FAIRFIELD, N.J., July 17 /PRNewswire-FirstCall/ -- Arno Therapeutics, Inc. (OTC Bulletin Board: ARNI), today announced that its stock ticker symbol on the OTC Bulletin Board has changed from "LRRI.OB" to "ARNI.OB" effective July 17, 2008.

About Arno Therapeutics

Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes innovative products for the treatment of cancer patients. Arno's lead compound is AR-67, a novel, third-generation camptothecin analogue in Phase I studies in patients with advanced solid tumors that has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. Arno is also developing two pre-clinical compounds. AR- 12 is a potential first-in-class, orally available PI3-k/Akt inhibitor undergoing IND-enabling studies. AR-42 is an orally available, targeted inhibitor of the Pan-DAC and Akt pathways also undergoing IND-enabling studies. Arno is actively pursuing additional compounds to expand its portfolio. For more information on Arno please visit http://www.arnothera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, outlook, milestones, the success of Arno's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking
'/>"/>

SOURCE Arno Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Silence Therapeutics Announces Successful Opposition of Glover Patent
3. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
4. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
5. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
6. Nabriva Therapeutics Announces Appointment of New CEO
7. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
8. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
9. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
10. Tobira Therapeutics Inc. Announces Senior Management Team
11. Duska Therapeutics Obtains Standard & Poors Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Grove, PA (PRWEB) August 28, 2014 ... and create a culture that will allow individuals to ... are becoming increasingly important for employers looking to compete ... science industries are embracing this trend, as the sector ... fabric of a company, which will have real results ...
(Date:8/28/2014)... Sterlitech is proud to announce that ... stable of products . These additional products ... include membrane filters with surface charges. , ... for our membrane process testing equipment, and correspondingly, a ... membranes,” explains Sterlitech President Mark Spatz. “The addition ...
(Date:8/28/2014)... Scientists, researchers, and technologists will converge in ... 2014 symposium. Marking its 46th year, the annual ... 14-17 September. The event is sponsored by SPIE, ... The premier conference for basic and applied issues which ... will engage researchers and engineers from numerous industries and ...
(Date:8/28/2014)... Boston, MA (PRWEB) August 28, 2014 ... of wholesale construction materials, selected SoundConnect ... of their cloud based audio and web conferencing ... configured to support PrimeSource’s employees’ needs. SoundConnect ... technologies. , PrimeSource Building Products will be ...
Breaking Biology Technology:Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3PrimeSource Chooses SoundConnect as Collaboration Provider 2
... SAN DIEGO , June 2, 2010 Amylin Pharmaceuticals, Inc. ... Conference in New York on Wednesday, June 9, 2010 ... Mark Foletta , senior vice president, finance and chief financial officer ... , , ...
... , June 2 The Libyan government has instructed UK-based ... work on the remains of the passengers who died when Afriqiyah Airways ... , , , ... the 104 people onboard the Airbus A330-200 perished - with 70 of ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today announced the promotion ... as the company,s Vice President, Chief Accounting Officer since joining BioMed in ... , "I am ... Griffin , BioMed,s President and Chief Operating Officer. "Greg has been an integral ...
Cached Biology Technology:Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference 2Libyan Air Crash DNA Samples to Trimega Laboratories for Analysis 2BioMed Realty Trust Promotes Greg Lubushkin to Chief Financial Officer 2BioMed Realty Trust Promotes Greg Lubushkin to Chief Financial Officer 3
(Date:8/29/2014)... U.S. Ebola researcher from the University of Texas Medical Branch ... of three monoclonal antibodies can completely protect monkeys against a ... infection, at a time when the disease is severe. , ... editorial for Nature discussing advances in Ebola treatment ... are among the most deadly of pathogens, with fatality rates ...
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
(Date:8/29/2014)... available in German . ... organisms is considered the oldest form of communication. Acting ... for example, the sexual attraction between males and females. ... to coordinate reproductive behavior in males and females. Scientists ... the Algarve in Faro, Portugal, and at the Max ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3
... or micro brew-beer that you drank in Pittsburgh, Dallas, Denver ... related to geographic location. When you consume these beverage you ... be used to track your travels over time, a new ... effort to describe the use of beverages as a potential ...
... More electrodes and a thinner, more flexible wire ... cochlear implants, a team of Medical College of Georgia ... for cochlear implantsan estimated million in the United States ... ears. An implant does not restore normal hearing but ...
... to the sea could decrease viral infection rates among ... a means by which carbon is transferred from the ... mathematical modelling study. The findings, published in the ... geo-engineering schemes proposed for tackling global warming. Tiny ...
Cached Biology News:Beverages leave 'geographic signatures' that can track people's movements 2New cochlear implant could improve outcomes for patients 2Nutrients, viruses and the biological carbon pump 2
Mycoplasma tested...
Alkaline Phosphatase Stabilizer Solution, 1 L...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
Biology Products: